Browsing by Subject "lung diseases"

Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    EMPHYMAB BIOTECH, MEDICAL THERAPIES FOR EMPHYSEMA
    (Office of the Vice Chancellor for Research, 2013-04-05) Johnstone, Brian; Claus, Matthias; Petrache, Irina
    Emphymab™ Biotech was formed to develop and commercialize medical therapies that address serious lung diseases. The founders are scientists and clinicians at Indiana University School of Medicine. Emphymab’s lead technology is based on a novel monoclonal antibody that inactivates a newly discovered pathway involved in lung diseases and, thereby, halts progressive loss of lung function associated with emphysema. This technology has the potential to address the huge unmet medical need of patients suffering from chronic obstructive pulmonary disease (COPD) with emphysema, which is the 3rd leading cause of death worldwide.
  • Thumbnail Image
    Item
    Extracellular vesicles: novel communicators in lung diseases
    (BMC, 2020-07-08) Mohan, Aradhana; Agarwal, Stuti; Clauss, Matthias; Britt, Nicholas S.; Dhillon, Navneet K.; Medicine, School of Medicine
    The lung is the organ with the highest vascular density in the human body. It is therefore perceivable that the endothelium of the lung contributes significantly to the circulation of extracellular vesicles (EVs), which include exosomes, microvesicles, and apoptotic bodies. In addition to the endothelium, EVs may arise from alveolar macrophages, fibroblasts and epithelial cells. Because EVs harbor cargo molecules, such as miRNA, mRNA, and proteins, these intercellular communicators provide important insight into the health and disease condition of donor cells and may serve as useful biomarkers of lung disease processes. This comprehensive review focuses on what is currently known about the role of EVs as markers and mediators of lung pathologies including COPD, pulmonary hypertension, asthma, lung cancer and ALI/ARDS. We also explore the role EVs can potentially serve as therapeutics for these lung diseases when released from healthy progenitor cells, such as mesenchymal stem cells.